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Abstract
Introduction: Approximately 35% patients with papillary thyroid carcinoma (PTC) and 13%
with  follicular  thyroid carcinoma  (FTC)  present  with metastases  of  cervical  lymph  nodes
(LNs)  at  the  time  of  diagnosis.  In  addition,  15–20%  of  patients  treated  with  total
thyroidectomy  develop,  after  an  interval  of  five  years,  metastases  to  the  neck  LNs  on
ultrasound examination. Fine-needle aspiration biopsy (FNAB) represents the gold standard
technique for the detection of cervical LNs metastases. The aim of the study was to evaluate
the diagnostic performance of  the technique of  thyroglobulin (Tg) measurement of washout
FNAB (FNAB-Tg)  in  diagnostics  of  LNs metastases  in  different  groups  of  patients  with
differentiated thyroid carcinoma (DTC). 
Material and methods: Two hundred FNAB-Tg samples from 200 patients [158 women; 42
men; mean age 51.37 ± 16.77 (53)] diagnosed with DTC were examined for the assessment of
the diagnostic utility of FNAB-Tg from suspicious LNs. FNAB-Tg ranged from 1.96 to 5000
ng/mL in metastatic LNs [mean; 1510 ± 1486 ng/mL (958.5)] and from 0.04 to 635.9 ng/mL
in nonmetastatic LNs [mean; 57.86 ± 319.19 ng/mL (1.96)], p < 0.001.
Results: The most accurate diagnostic  performance was displayed for the concentration of
33.28 ng/mL in FNAB-Tg with AUC of 0.91 and high sensitivity and specificity (0.92 and
0.93). FNAB-Tg in conjunction with the cytopathological examination of suspicious LNs in
differentiated thyroid carcinoma (DTC) patients increases the diagnostic accuracy of FNAB
(sensitivity 0.99; specificity 0.99; AUC 1.00). 
Conclusions: FNAB-Tg  may  be  particularly  useful  in  detecting  LN  metastases  in  DTC
patients,  and  in  differential  diagnosis  of  various  LN  metastasizing  malignancies. The
combination of FNAB and FNAB-Tg measurement has high specificity and sensitivity in the
detection of LN metastases of DTC.
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Introduction
Differentiated thyroid carcinomas (DTC) usually behave in an indolent fashion and have an
excellent prognosis. Nevertheless, DTC is frequently associated with cervical lymph nodes
(LNs), and approximately 35% of patients with papillary thyroid carcinoma (PTC) and 13%
of patients with follicular thyroid carcinoma (FTC) present LNs metastasis  at  the time of
diagnosis [1]. Moreover 5–20% of patients will develop LN metastases during the first five
years after treatment, and recurrences may appear up to 20 years after initial treatment [2].
Ultrasonography  (US)  is  currently  the  most  useful  method  to  detect  cervical
lymphadenopathy; however, none of the suspicious US findings (round shape, cystic changes,
hyperechoic foci or microcalcifications, irregular chaotic vascularization, and absence of the
hilus) allows the formulation of a diagnosis of LN metastasis [3, 4]. Consequently, fine-needle
aspiration  biopsy  (FNAB)  is  usually  required  to  confirm  or  exclude  metastasis  because
reactive LN enlargement is common in the neck region. However, small LNs are technically
difficult to aspirate. On the other hand, evaluation of enlarged neck LNs may be challenging
due to the broad spectrum of non-thyroidal lesions presenting as a neck nodule. Moreover,
cytological  features  of  enlarged  LNs  are  difficult  to  evaluate  due  to  the  presence  of
lymphocytes, granulocytes, and multinucleated giant cells, a variable amount of necrosis, and
poor epithelial cellularity, particularly in the case of cystic changes [5]. This results in a 6–8%
false-negative rate and a 5–10% inadequacy rate of FNAB [6]. 
The thyroglobulin (Tg) measurements in the needle washout (FNAB-Tg) have been reported
to increase the sensitivity of FNAB [7].  This  technique is  particularly useful in detecting
cystic and small  metastases. FNAB-Tg was found to be helpful in cases of indeterminate
cytopathology and in patients suffering from other malignancies beside DTC. The rationale of
the technique comes from the fact that Tg is produced only by follicular cells. Consequently,
detection of Tg in LNs FNAB suggests the diagnosis of DTC metastasis. This assay was first
proposed by Pacini et al., and despite being recommended by many guidelines the technique
is not standardized [8]. There are considerable differences between various diagnostic centres
regarding the methodology of measurement of Tg levels as well as cut-off values for FNAB-
Tg in positive cases (varying from 0.2 ng/mL to 100 ng/mL in different studies) [9]. 
Nevertheless FNAB-Tg became a gold standard at many centres in the follow-up of DTC
patients,  with  sensitivity  and  specificity  of  92-100% and  89-100%,  respectively  [10,11].
Current clinical practice guidelines for thyroid carcinoma already incorporate FNAB-Tg as an
essential addition to FNAB in suspicious LNs [12].
However, the results of FNAB-Tg may be influenced by many factors, including the presence
of a normal thyroid (in patients before surgery or after lobectomy) and the presence of serum
Tg antibodies (TgAb) [13,14,15].
In the present study we aimed to evaluate the diagnostic performance of FNAB-Tg and its
cut-off value in diagnostic LN metastases in DTC patients. 
Material and methods
Patients
Two hundred LN FNAB-Tg samples from 200 patients [158 women and 42 men; age 51.37 ±
16.77 (53)] with suspicious neck LNs were investigated. All the patients were diagnosed with
DTC, treated and followed up at the Department of Oncological Endocrinology and Nuclear
Medicine, Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw. The
patients were recruited between 2012 and 2015. FNAB and FNAB-Tg measurements were
performed  at  initial  diagnosis  of  thyroid  cancer  prior  to  thyroidectomy or  during  cancer
surveillance  after  thyroidectomy  and/or  radioactive  iodine  therapy/or  radiotherapy.  The
inclusion  criteria  were  as  follows:  confirmed  cytopathological  (Bethesda  VI)  or
histopathological  DTC,  suspicious  LNs  in  US.  The  following  exclusion  criteria  were
introduced: 1) metastases to LNs from primary lesions other than DTC, such as anaplastic
thyroid carcinoma or medullary thyroid carcinoma; 2) LNs without serum Tg and TgAb at the
time of FNAB and FNAB-Tg measurement; and 3) LNs without follow-up at our institution
after the first FNAB and FNAB-Tg. This study complied with the ethical standards of the
Declaration of Helsinki and was approved by the Ethic Committee of Maria Sklodowska-
Curie  National  Research  Institute  of  Oncology in  Warsaw.  The requirement  for  informed
consent explaining the study purpose and procedures was waived due to the retrospective
design of this study.
US-guided FNAB and FNAB-Tg of suspicious LNs 
FNAB was performed by an experienced cytopathologist with a 25-gauge needle attached to a
10 mL disposable plastic syringe under the real-time guidance of a US device (iU22 Philips
diagnostic ultrasound system — Philips Ultrasound, with a L12-5 MHz compact linear array
transducer).  US criteria  indicating suspicious  LNs included the following:  absence of  the
hilus,  prominently  hypoechoic,  presence  of  cystic  changes,  presence  of  calcifications,  a
rounded (longitudinal/transverse axis < 2) or polycyclic shape, and irregular and/or peripheral
vascularity.  The specimen obtained from FNAB was immediately smeared on glass slides
after aspiration, fixed with 70% ethanol, and stained with haematoxylin and eosin (H&E)
stain. 
The remaining aspirate in the syringe and needles were immediately rinsed with 0.5 mL of
isotonic  0.9%  saline  and  the  washouts  were  processed  to  measure  Tg  using  the
electrochemiluminescent (ECLIA) assay by an Elecsys cobas e automated analyser (ROCHE).
The value below a lower range of the detection limit was < 0.04 ng/mL and above it was >
5000  ng/mL.  The  threshold  values  were  3.5–77  ng/mL  respondent  with  2.5  and  97.5
percentiles. Positive FNAB-Tg was defined as a concentration of Tg in washout above the
cut-off value. Normalized washout Tg was defined as the FNAB-Tg divided by the serum Tg
level. 
Biochemical analysis: Tg and TgAb
Serum Tg, FNAB-Tg, and serum antibodies (TgAb) samples were taken from all the patients.
The serum Tg and FNAB-Tg were measured as above, and TgAb was measured using the
electrochemiluminescent (ECLIA) assay by an Elecsys cobas e automated analyser (ROCHE).
The value below a lower range of the detection limit was < 10.0 IU/mL and above it was >
4000 IU/mL. The threshold value was 115 IU/mL respondent with the 94th percentile.
Fine-needle aspiration biopsy (FNAB) results and final LN diagnosis 
The interpretation of FNAB was performed by experienced pathologists specialized in thyroid
cytology. The results of the microscopic examinations were classified into three groups:
1) positive — presence of carcinoma cells; 2) negative — absence of carcinoma cells; and 3)
indeterminate or non-diagnostic — poorly cellular smears, presence of macrophages and/or
some  suspicious  epithelial  cells  without  clear  (convincing)  signs  of  malignancy,  or  poor
specimen with absence of LN elements and epithelial cells. The patients with indeterminate or
non-diagnostic cytopathology results underwent repeated FNAB and FNAB-Tg. 
Patients with positive FNAB and/or FNAB-Tg results of the aspirated LNs were qualified for
appropriate  treatment  — surgery,  systemic  treatment  (disseminated  diseases),  or  watchful
waiting  (patients  who did not  agree to  treatment).  Generally,  the  final  LN diagnosis  was
confirmed by postoperative histopathologic results.  Metastatic  LNs were defined as  those
with postoperative metastasis  in histopathology in the same compartment  that  FNAB and
FNAB-Tg were performed. If  patients did not undergo surgical  treatment,  metastatic LNs
were defined based on metastatic FNAB results combined with a high FNAB-Tg level and
results of imaging studies (US, computed tomography - CT, magnetic resonance imaging -
MRI).  If  repeated  FNAB  showed  metastatic  carcinoma  cells  LNs  were  included  in  the
metastatic group. Benign LNs were confirmed by benign histopathology after post-operative
review. If the target LNs were not dissected and follow-up imaging showed decreased size or
no interval  change in  size  during  a  follow-up of  at  least  five  years,  the  final  LNs were
considered to be benign. If repeat FNAB results revealed benign LNs, the final LNs were also
defined as benign. LNs that were negative in FNAB and in FNAB-Tg were subjected to US
and clinical follow-up for at least 60 months.
Statistical analysis
Data  analysis  was  performed  using  R  software  (version  3.6.1).  The  χ2 test  was  used  to
compare  the  groups  of  data  that  did  not  meet  the  assumptions  of  the  parametric  test
(parametric tests were conducted using Student’s t-tests). Associations between variables were
analysed using Pearson’s correlation coefficient (point-biserial correlation when one variable
was dichotomous). The receiver operating characteristic (ROC) was used to determine the
best  cut-off  values  for  diagnostic  purposes  of  the  analysed  variables.  In  each  case  the
sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV)
were assessed. For each variable, the 95% confidence interval (95% CI) was estimated. In all
analyses, the results were considered statistically significant when p < 0.05. To measure the
predictive capabilities of the models, four-fold cross-validation was performed. The approach
was selected to assess how the results of a statistical analysis generalize to an independent
dataset  (new patients).  The main goal  of  cross-validation is  to  test  the  model’s  ability to
predict new data that was not used in the rule selection. This approach is commonly used to
overcome overfitting problems or selection bias.
Results
The analysis of the 200 LNs revealed 60 to be metastatic, whereas the remaining 140 lymph
nodes  had  no  signs  in  neoplastic  process  upon  cytopathological  and/or  histopathological
examination. Statistical analysis revealed that patients with the presence of metastatic lymph
nodes had significantly higher Tg serum, as well as FNAB-Tg levels; however, the level of
TgAb did not differ significantly (Tab. 1). In metastatic cases no significant correlation of Tg
serum and FNAB-Tg levels could be disclosed (r = 0.15, p = 0.2467). However, there was
observed correlation in the case of cancer-free patients (r = 0.2, p = 0.0214). In all analysed
lymph nodes the Tg serum also (significantly) correlated with the FNAB-Tg level (r = 0.26, p
< 0.001).
ROC analysis was performed to identify the best markers for discrimination of metastatic LNs
(Fig.  1).  The  analysis  revealed  that  threshold  based  on FNAB-Tg  and  FNAB give  most
accurate results. However, due to the high level of variation of FNAB-Tg (standard deviation
=  1082.27),  there  is  high  risk  of  selection  bias  (another  random  group  of  patients  can
represent slightly different level of FNAB-Tg). In order to overcome this limitation, four-fold
cross-validation was performed. The results of cross validation confirm that the addition of
FNAB-Tg to cytopathological examination increased the sensitivity and negative predictive
value as compared to solitary analysis of FNAB or FNAB-Tg (Tab. 2). Based on the obtained
results, the combination with a cut-off value of FNAB-Tg of 33.28 ng/mL was selected. For
100 randomly selected patients, it  successfully identified all metastatic LNs; however, two
false-positive results were derived. In order to increase the diagnostic potential of FNAB-Tg,
a combination of its level and results of cytopathological specimen analyses were combined.
Applying the FNAB-Tg threshold (33.28 ng/mL) to the FNAB cytopathology produced more
accurate results (Fig. 2).
Patients with follicular thyroid carcinoma (FTC)
Fifteen patients were diagnosed with FTC. In seven patients positive results of the FNAB
correlated  with  elevated  FNAB-Tg  level.  In  the  follow-up  in  four  of  these  patients,
histopathological examination of the removed LNs disclosed metastases, in two cases with a
minor  component  of  the  poorly  differentiated  carcinoma.  Three  patients  with  positive
correlation  of  FNAB  and  elevated  FNAB-Tg  levels  were  not  operated  on  because  of
disseminated neoplastic process or disqualification caused by accompanying diseases. One
patient with elevated FNAB-Tg and negative FNAB was operated on with histopathological
examination revealing LN metastasis, and in five years of follow-up nodal recurrence was
noticed.
Five years of US observation of an additional seven patients with negative FNAB and low
FNAB-Tg level indicated a reduction of the enlarged LNs, but in two patients in this group an
incomplete biochemical response was observed. 
Patients with Hürthle cell carcinoma
Hürthle cell carcinoma usually has a more aggressive clinical course, often with metastasis to
the  neck  LNs  and  worse  prognosis  [16,  17].  Four  patients  were  diagnosed  with  this
classification of thyroid tumours. In two patients, positive results of the FNAB correlated with
elevated FNAB-Tg levels. One patient was operated on, and histopathological examination of
the  removed  LNs  disclosed  metastasis  of  both  Hürthle  cell  carcinoma  and  poorly
differentiated  components;  two  years  after  lymphadenectomy the  patient  died  because  of
disseminated neoplastic disease. The other patient was disqualified from operation because of
metastases  to  the  lungs.  In  an  additional  two  patients  FNAB  and  FNAB-Tg  remained
negative, and in one patient five-year follow-up US examination indicated benign LNs with
incomplete  biochemical  response;  in  the  second case,  recurrence  in  the  thyroid  beds  and
metastases to the lungs were observed.
Patients with papillary thyroid carcinoma (PTC)
In 46 patients with PTC positive results of FNAB correlated with elevated FNAB-Tg levels.
In the follow-up in 39 of these patients, histopathological examination of the removed LNs
disclosed  metastases,  in  one  case  with  a  minor  component  of  the  poorly  differentiated
carcinoma. Thirteen patients displayed discordant results between FNAB and FNAB-Tg. In
two  of  these  patients  with  positive  FNAB  and  low  FNAB-Tg  levels  histopathological
examination of the resected LNs revealed either a diffuse sclerosing variant of PTC or widely
disseminated PTC. Two of the five patients with high FNAB-Tg level and negative FNAB
underwent surgery, and histopathological examination of excised LNs confirmed metastases
in one case. 
Among  45  patients  after  lymphadenectomy  with  histopathologically  confirmed  LN
metastases, 33 patients did not develop biochemical or structural recurrence disease after five
years  of  follow-up,  another  two  patients  presented  LN  metastases  after  one  year  of
observation, and two cases had nodal recurrence five years after surgical treatment. In six
patients  in  tbis  group  incomplete  biochemical  response  was  observed  after  five  years  of
follow-up.
In a group of 13 patients with positive FNAB or/and elevated FNAB-Tg disqualified from
lymphadenectomy five  patients  remained  in  the  five-year  follow-up.  In  two  of  them not
qualified for surgical treatment because of equivocal FNAB or FNAB-Tg recurrence was not
observed.  Another  three  patients  with  inoperable  nodal  recurrence  did  not  develop
progression.
In a group of 123 patients with negative FNAB and FNAB-Tg below cut-off value five years
of the follow-up underwent  104 patients.  In  this  group neither  biochemical  nor  structural
recurrence was observed. In cases of enlarged LNs in US examination, FNAB or FNAB-Tg
did not  confirm suspicion of  metastases.  Another  five patients  presented only incomplete
biochemical response.
Patients after external beam radiotherapy of the neck 
Thirty-three patients with locally advanced neoplasms (pT3, pT4, N1, R1) and infiltration of
the perinodal adjacent tissue underwent external beam radiotherapy of the neck area. In 20 of
these patients radiotherapy was performed before FNAB of suspicious LNs, and in 14 patients
positive  FNAB correlated  with  FNAB-Tg  above  the  cut-off  value.  Seven  of  them were
operated with histopathologically confirmed metastases in resected LNs. The others seven
patients were disqualified from surgical treatment because of disseminated neoplastic disease.
Patients with DTC and poorly differentiated carcinoma
In five patients with DTC histopathological examination disclosed an admixture of the poorly
differentiated carcinoma. Positive FNAB cytopathology of the suspicious LNs correlated with
elevated  FNAB-Tg  level  in  four  of  these  patients.  In  four  patients,  histopathological
examination of the excised LNs confirmed metastases,  while one patient  did not  undergo
lymphadenectomy because of disseminated diseases with metastases to the lungs. Only in one
operated patient was recurrence of carcinoma not observed in five years of observation; in an
additional three cases disseminated neoplastic disease was the cause of death after one to four
years of follow-up.
Patients with DTC and additional neoplasm
Eight patients with DTC and a history of additional neoplasm were examined by FNAB and
FNAB-Tg of suspicious neck LNs. Positive FNAB of metastatic breast carcinoma, squamous
cell carcinoma, and lymphoma correlated with low FNAB-Tg levels in three cases. In one
patient with a history of parathyroid carcinoma FNAB of the lump in the neck disclosed
follicular-like cells but the FNAB-Tg level was low. Complementary examination disclosed a
high level  of  parathormone (PTH) in  the  needle  washout,  indicative  of  metastasis of  the
parathyroid carcinoma. Histopathological examination of the excised mass revealed benign
parathyroid adenoma. In one patient treated for colonic adenocarcinoma the FNAB-Tg level
was clearly elevated (> 2500 ng/mL) in concordance with positive FNAB cytopathology of
enlarged LNs. Histopathological examination of the excised LNs disclosed cystic metastasis
of the PTC. In one patient with a history of embryonal carcinoma in a testis, positive FNAB
cytopathology and elevated FNAB-Tg level were suggestive of PTC metastasis. Subsequent
thyroidectomy and neck LN dissection confirmed PTC in the isthmus of a thyroid. 
Discussion
Sources of heterogeneity
Although US-guided FNAB is a well establish diagnostic procedure, the accuracy and results
of this examination depend on the skill of the radiologists and pathologists performing the
aspiration [18]. 
Almost all authors selected LNs to FNAB on the basis of increased size and suspicious US
findings, such as round shape (longitudinal to transverse axis ratio < 2 or transverse axis > 5
mm), the absence of an echogenic hilus, microcalcifications, cystic change, heterogeneous
echogenicity, and peripheral or ‘chaotic’ vascularity [19–21]. The authors confirmed in the
study the significant correlation of the existence of some US features in discriminating benign
and metastatic LNs (Tab. 3).
Preoperative vs. postoperative assessment 
The contamination of the FNAB-Tg washout sample with blood containing Tg may influence
the results of the examination and the specificity of this method. Blood in individuals with an
intact  thyroid or after  lobectomy would be expected to  have higher  circulating serum Tg
compared to patients after thyroidectomy [22]. Another study revealed that remnant thyroid
tissue has no impact on the diagnostic performance of the FNAB-Tg level [23]. In our group
of patients there was no correlation between serum Tg and FNAB-Tg. FNAB-Tg above the
cut-off level was observed in patients with low Tg serum level, which could not be explained
by blood  contamination.  However,  in  patients  before  thyroidectomy the  authors  revealed
statistically higher FNAB-Tg levels. Furthermore, it was hypothesized that the serum TSH
level could also affect FNAB-Tg, independently of its effect on the serum Tg level. In other
terms, in patients after thyroidectomy, serum TSH suppression may play a role in the lowering
of  both  serum Tg and FNAB-Tg,  together  with  the  absence  of  thyroid  tissue [22].  Most
patients in this study underwent FNAB after thyroidectomy and under TSH suppression.
Interference of antibodies
The interference of TgAb when measuring serum Tg is well known, and FNAB-Tg might also
be affected by positive TgAb, which occurs in approximately 20-25% of patients with DTC
and in approximately 10% of the whole population [24, 25]. The presence of TgAb may be a
result of contamination of the wash-up sample with blood, but also by antibodies produced in
the lymph nodes [26].  In previous publications some authors excluded patients with high
levels of serum TgAb from the FNAB-Tg examination. However, Baskin et al. concluded in
their study that FNAB-Tg was not affected by positive TgAb in the serum [26]. Boi et al.
found that  the presence of TgAb in wash-up liquid may cause an underestimation of the
FNAB-Tg level, but this interference has little influence on the test and no false-negative case
was recorded [25]. The results of our study confirm a limited effect of TgAb on the diagnostic
significance of FNAB-Tg, and there was no significant discordant results between elevated
TgAb level and FNAB-Tg (r = –0.17, p = 0.4434).
Cut-off levels 
The last meta-analysis based on the largest published studies found that a FNAB-Tg cut-off
value of 1 ng/mL had highest sensitivity and 40 ng/mL had highest specificity [9]. An FNAB-
Tg cut-off value has not been unanimously established. Cut-off values ranging from 0.2 to
100 ng/mL have been suggested for FNAB-Tg. Some authors set the threshold to the mean
value  of  2  SD for  the  negative  patients,  while  others  used  the  highest  Tg  concentration
measured in patients with reactive LNs, the upper value of reference range of serum Tg, the
functional  sensitivity  of  the  assay,  or  the  best  cut-off  derived  by  a  receiver  operating
characteristic (ROC) curve analysis. Some studies adopted an FNAB-Tg cut-off equal to the
serum Tg concentration [22]. Our subgroup analysis supports the choice of a 33.28 ng/mL
cut-off value for FNAB-Tg, but the results are affected by a significant heterogeneity between
studies (Tab. 4). An FNAB-Tg level below the cut-off value was observed in seven metastatic
patients. The lowest values of FNAB-Tg in the FNAB cytopathologically positive group were
observed in patients with PTC ‘tall cell’ variant (1.56 ng/mL) and in patients with Hürthle cell
carcinoma with a minor component of the poorly differentiated carcinoma (1.96 ng/mL). It
should be taken into consideration that in the case of positive FNAB cytopathology, the low
FNAB-Tg value should not influence the therapeutic decision on lymphadenopathy because
of decreased Tg production by some aggressive variants of DTC and poorly differentiated
carcinoma [27, 28]. Further studies are needed to clarify the FNAB-Tg cut-off value and to
elucidate whether this should be different in patients before and after thyroidectomy. 
The heterogeneity of the treatment groups vs. FNAB-Tg assessment
The majority of patients in our study were diagnosed with PTC (n = 181), similarly to its
relative worldwide incidence. Statistical analysis revealed that this group was younger (p =
0.02) and characterised with higher,  but not  statistically significant,  FNAB-Tg value (p =
0.75) and lower Tg serum value (p = 0.08), which might be the effect of the strength of this
group and the fact that metastases in LNs were confirmed in 60 patients in the whole group.
The  majority  of  patients  with  positive  FNAB  and  FNAB-Tg  had  histopathologically
confirmed LN metastases. Patients with benign LNs did not develop recurrence in five years
of follow-up. The group of 15 patients diagnosed with FTC were older compared with the
whole group of patients (p = 0.19) and were characterised by higher FNBA-Tg (p = 0.96) and
Tg  serum values  (p  =  0.08).  Patients  with  FTC developed  a  more  aggressive  course  of
neoplastic  disease  precluding  surgical  treatment  in  some  cases.  In  all  four  patients  who
underwent  lymphadenectomy  over  seven  with  positive  FNAB  and  FNAB-Tg  were
histopathologically confirmed of LNs metastases. Four patients from all the cases in the study
were diagnosed  with Hürthle cell carcinoma. Those patients were statistically significantly
older (p = 0.02) with lower both FNAB-Tg (p < 0.05) and Tg serum (p = 0.25). Two patients
in  this  group  had  positive  FNAB  and  FNAB-Tg;  one  of  them  was  operated  with
histopathological confirmation of LN metastases. In one case from this group, with negative
FNAB and FNAB-Tg, we observed recurrence in the thyroid bed, which confirmed a more
aggressive course of disease in Hürthle cell carcinoma. According to our statistical analysis,
we confirmed the usefulness of FNAB-Tg in the diagnosis of LN metastases in patients who
underwent external beam radiotherapy of the neck before FNAB. This group of patients were
characterised by older age, more aggressive course of neoplastic disease, and what is worth
emphasizing, statistically significantly higher FNAB-Tg value (p = 0.01).  We confirmed in
our study a high sensitivity and specificity of the combination of FNAB and FNAB-Tg in the
whole group of patients, and the heterogeneity of their strength precludes the establishment of
different FNAB-Tg cut-off values in each group. For this purpose, further research should be
done.
Conclusions
A combination  of  FNAB  and  FNAB-Tg  is  an  excellent  diagnostic  procedure  for  LN
metastasis  of  DTC.  Compared  to  FNAB  and  FNAB-Tg  alone,  the  combination  could
statistically improve the diagnostic performance. This procedure should be recommended for
patients with suspicious LN metastases of DTC after initial therapy.
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Table 1. Numeric variable values: mean ± standard deviation (SD) (median)










87.87  ±  531.98
(0.49)










57.45  ±  266.23
(10.21)
87.7 ± 367.97 (10.52)







493.54  ±  1082.27
(3.5)
1510.12  ±  1486.36
(958.5)







310.56  ±  1645.89
(3.98)
479.3  ±  1627.71
(28.89)























LNs — lymph nodes; Tg — thyroglobulin; TgAb —Tg antibodies;  FNAB — fine-needle
aspiration biopsy; Tg ratio — FNAB-Tg/serum Tg; TSH — thyrotropin
Table 2. Summary of results for thyroglobulin (Tg), thyroglobulin (Tg) measurements in the needle
washout  (FNAB-Tg),  positive  fine-needle  aspiration  biopsy [FNAB(+)],  and  FNAB(+)  with
FNAB-Tg (four-fold cross validation).
Test Sensitivity Specificity PPV NPV AUC PLR NLR p value
Tg 0.84 0.80 0.64 0.93 0.86 33.95 0.19 < 0.000
FNAB-Tg 0.92 0.93 0.84 0.97 0.91 213.31 0.08 0.001
FNAB(+) 0.97 0.99 0.98 0.99 0.98 738.56 0.03 < 0.001
FNAB(+) and FNAB-Tg 0.99 0.99 0.98 1.00 1.00 751.82 0.01 < 0.001
PPV — positive predictive value; NPV — negative predictive value; AUC — area under
curve; PLR — positive likelihood ratio; NLR — negative likelihood ratio



























































































LNs — lymph nodes
Table 4. Confusion matrix for all patients and thyroglobulin (Tg) measurements in the needle
washout (FNAB-Tg) cut-off value 33.28 ng/mL
Metastatic LNs Benign LNs
FNAB-Tg level+ 53 9
FNAB-Tg level– 7 131
LNs — lymph nodes
Figure 1. ROC curve for selected markers (re-substitution method). Tg — thyroglobulin;
FNAB — fine-needle aspiration biopsy; FNAC — fine-needle aspiration cytopathology; Tg
ratio — FNAB-Tg/serum Tg
Figure 2. Nomogram for thyroglobulin (Tg) measurements in the needle washout (FNAB-Tg)
level and FNAB(+) cytopathology (four-fold cross-validation).  Using combined information
about  FNAB  cytology  result  and  FNAB-Tg  level  gives  a  98%  chance  that  a  positively
diagnosed patient will be finally diagnosed as metastatic

